Biomarkers for Patient Selection Banner

May 17-18

Opening Plenary Session

Big Data and the Evolution of Precision (Personalized) Medicine

George Poste, Ph.D., Chief Scientist, Complex Adaptive Systems, Professor, Health Innovation, Arizona State University

Next Steps in Cancer Immunotherapy

Eric H. Rubin, M.D., Vice President and Therapeutic Area Head, Oncology Early Development, Merck Research Laboratories

Biomarkers to Predict Response to Therapy

Use of Epigenetic Markers as Markers for Response in Clinical Trials

Jeffrey Waring, Ph.D., Director, Pharmacogenetics and Pharmacogenomics, Abbvie

Alpha E is the Target for Etrolizumab Treatment for Inflammatory Bowel Disease and May Predict Responses to Treatment

Teresa Ramirez Montagut, Ph.D., Scientist, Development Sciences, Genentech

Genomic Markers of Response to Anti-HER2 Therapies in Breast Cancer

Christos Hatzis, Ph.D., Assistant Professor, Medicine, and Director, Bioinformatics, Breast Medical Oncology, Yale Comprehensive Cancer Center, Yale University School of Medicine

Development of a Drug-Response Modeling Framework to Identify Cell Line-Derived Translational Biomarkers that Can Predict Treatment Outcome

William Trepicchio, Ph.D., Senior Director, Translational Medicine, Takeda

The Impact of Genomic Research during Drug Development

Rebecca Blanchard, Ph.D., Executive Director, Genetics and Pharmacogenomics, Head of Clinical Pharmacogenomics and Operations, Merck

Genomic Profiling: Mutation Analysis for Personalized Therapy

Clinical Genomics of Solid and Liquid Biopsies in Patients with Solid Tumors

Marc Ladanyi, M.D., Attending Pathologist and Chief, Molecular Diagnostics Service; Member, Human Oncology and Pathogenesis Program, Memorial Sloan-Kettering Cancer Center, New York

Utility of Multi-Faceted Approaches for Biomarker Discovery

Darrell R. Borger, Ph.D., Director, Biomarker Laboratory, Co-Director, Translational Research Laboratory, Massachusetts General Hospital Cancer Center

Identification of Patient Subgroups through the Analysis of Blood RNA Profiling Data

Christopher Roberts, Ph.D., Associate Director, Computational Biology, Biogen Idec

Precision Medicine: Patient Stratification Strategies

Biomarkers for Patient Stratification and Precision Medicine: Cancer and Beyond

Jaya Goyal, Ph.D., Senior Director, Precision Medicine, Value Based Medicine, Biogen

Patient Selection Biomarkers – From the PDX Model Directly to the Clinic

Ann Kapoun, Ph.D., Vice President, Translational Medicine, OncoMed Pharmaceuticals

Biomarker Tests for Molecularly Targeted Therapies: Key to Unlocking Precision Medicine

Debra G.B. Leonard, M.D., Ph.D., Chair and Professor, Department of Pathology and Laboratory Medicine, University of Vermont College of Medicine and Medical Center